| 000 | 01786 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517033322.0 | ||
| 264 | 0 | _c20151026 | |
| 008 | 201510s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/CP202032 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, Kyoung-Ah | |
| 245 | 0 | 0 |
_aComparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cAug 2015 |
||
| 300 |
_a667-73 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFebuxostat |
| 650 | 0 | 4 |
_aGout Suppressants _xadministration & dosage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aRepublic of Korea |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 650 | 0 | 4 |
_aThiazoles _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUric Acid _xblood |
| 650 | 0 | 4 |
_aXanthine Oxidase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPark, Ji-Young | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 53 _gno. 8 _gp. 667-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/CP202032 _zAvailable from publisher's website |
| 999 |
_c24923195 _d24923195 |
||